Clinical trials: Myeloid
Acute Myeloid Leukemia Refractory
Acute Myeloid Leukemia Treated With With NETrin Abs in Combination With [AZACITIDINE + VENETOCLAX]
The aim of this study is to investigate the safety and the clinical activities of NP137 when combined with Azacitidine and Venetoclax in patients with refractory acute myeloid leukemia after 2 cycles of Azacitidine and Venetoclax.
- Trial name
- AML-NET (NCT06150040)
- Testing
- NP137, Azacitidine Injection, Venetoclax
- Where
- France
- Volunteers
- 1 people
- Sponsor
- Centre Leon Berard
Multiple Myeloma, Non-Hodgkin Lymphoma
Preservation of Ovarian Function After Hematopoietic Cell Transplant
Women undergoing myeloablative allogeneic hematopoietic cell transplant (MA HCT) will receive GnRH agonist leuprolide. Women undergoing reduced intensity allogeneic (RIC) HCT will be observed.
- Conditions
- Multiple Myeloma, Non-Hodgkin Lymphoma, Hodgkin Disease, Acute Myeloid Leukemia
- Trial name
- NCT01343368
- Testing
- Leuprolide, hematopoietic cell transplant, reduced intensity allogeneic HCT
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Myelodysplastic Syndromes or Acute Myeloid Leukemia With Multilineage Dysplasia
Characterization of the Mechanisms of Resistance to Azacitidine
Myelodysplastic syndromes (MDS) are frequent diseases in elderly patients (median age: 71 years). IPSS classification defines low risk (Low and Intermediate 1), and high risk (Intermediate 2 and High) MDS.
- Trial name
- NCT01210274
- Where
- 4 sites in France, Monaco
- Volunteers
- 250 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Leukemia, Lymphoma
Chemotherapy Plus Donor White Blood Cell Infusion in Treating Patients With Relapsed Hematologic Cancer Following Donor Peripheral Stem Cell Transplantation
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. White blood cells from donors may be able to prevent graft-versus-host disease in patients with hematologic…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00005946
- Testing
- filgrastim, therapeutic allogeneic lymphocytes, cyclophosphamide
- Where
- United States
- Sponsor
- University of Maryland, Baltimore
Chronic Myeloid Leukemia, Chronic Phase
Observational Study on Chronic Myeloid Leukemia Patients in Any Phase Treated With Ponatinib (Iclusig®) at Any Dose
Additional information is needed to characterize the safety profile of ponatinib as it is used in routine clinical practice in Europe.
- Trial name
- Ponderosa (NCT03933852)
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- University of Jena
Acute Myeloid Leukemia and Myelodysplastic Syndrome
Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant
The purpose of the study is to determine the safety and benefit of nivolumab, ipilimumab or the combination of nivolumab with ipilimumab given after bone marrow transplant for patients with acute myelogenous leukemia and…
- Trial name
- CPIT-002 (NCT02846376)
- Testing
- Nivolumab, Ipilimumab
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Hackensack Meridian Health
Acute Myeloid Leukemia, Allogeneic Transplantation
Gemtuzumab Ozogamicin Before Allogeneic Stem Cell Transplantation
Study Design: prospective phase II trial with 30 patients in 1 site Treatment Scheme: Option 1: Patient < 60 years of age with relapse after chemotherapy or > 12 months after hematopoetic stem cell transplantation Mylotarg 6 mg/…
- Trial name
- NCT00460447
- Testing
- Gemtuzumab Ozogamicin
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- University Hospital Carl Gustav Carus
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
HEM-SURVIVE: Structuralized Follow-up for Childhood Hematological Malignancy Survivors
This study aims to construct a structuralized follow-up model for survivors of childhood hematological malignancies in China. Using a multicenter prospective cohort design, it will identify the burden and risk factors of late…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Lymphoma, Leukemia
- Trial name
- NCT07483749
- Where
- 3 sites in China
- Volunteers
- 400 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
Myeloproliferative Neoplasm, Acute Leukemia
Olverembatinib for FGFR1-rearranged Neoplasms
FGFR1-rearranged myeloid/lymphoid neoplasms are a rare hematologic malignancy with very poor outcome despite intensive chemotherapy.
- Trial name
- NCT05521204
- Testing
- Olverembatinib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Acute Myeloid Leukemia, Acute Lymphoid Leukemia
Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT
The study goal is to characterize the safety of the combination of Orca-T with dual agent GVHD prophylaxis.
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT06551584
- Testing
- ORCA-T
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Stanford University
Acute Myeloid Leukemia
Safety and Efficacy of Venetoclax, Cytarabine and Metformin (VenCM) for Relapsed-Refractory and Induction-Ineligible Acute Myeloid Leukemia
Phase 2 clinical trial to evaluate the combination of venetoclax, cytarabine and metformin in relapsed-refractory and induction ineligible acute myeloid leukemia.
- Trial name
- VenCM (NCT06537843)
- Testing
- Venetoclax, Cytarabine Injection, Metformin
- Where
- 5 sites in Brazil
- Volunteers
- 100 people
- Sponsor
- Hospital Municipal São José
Chronic Myelogenous Leukaemia
Phase II Study Testing the Tolerability and the Efficacy of Bosutinib in Chronic Phase CML Patients
Bosutinib is a 2nd generation tyrosine kinase inhibitor that has shown promising results from first up to fourth line treatment in patients with in chronic phase of chronic myelogenous leukaemia.
- Trial name
- BODO (NCT03205267)
- Testing
- Bosulif
- Where
- Germany
- Volunteers
- 127 people
- Sponsor
- University of Bonn
Leukemia
R115777 in Treating Patients With Refractory or Recurrent Acute Leukemia or Chronic Myelogenous Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of R115777 in treating patients who have refractory or…
- Trial name
- NCT00004009
- Testing
- tipifarnib
- Where
- 3 sites in United States
- Sponsor
- University of Maryland, Baltimore
Acute Myeloid Leukemia
Biomarkers for Personalized Early Assessment of Response During Salvage Chemotherapy in People With Relapsed or Refractory Acute Myeloid Leukemia (PEARL15)
Background: -Acute myeloid leukemia (AML) is a cancer of the white blood cells. It can be fatal. Standard treatment involves intensive chemotherapy. Not all treatment works.
- Trial name
- NCT02527447
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Chronic Myeloid Leukemia
Expanded Access Program of AMN107 in Imatinib-resistant or Intolerant Adult Patients With Chronic Myeloid Leukemia
This study will further evaluate if AMN107 is safe in adults with chronic myeloid leukemia who are resistant or intolerant to imatinib and to provide patients access to this new drug until the drug becomes commercially available.
- Trial name
- NCT00302016
- Testing
- AMN107
- Where
- 270 sites in United States, Australia and 32 more
- Sponsor
- Novartis Pharmaceuticals
Adult Acute Myeloid Leukemia in Remission
INFUSION OF ALLOREACTIVE NATURAL KILLER (NK) CELLS AS CONSOLIDATION STRATEGY FOR ACUTE MYELOID LEUKEMIA PATIENTS
Acute Myeloid Leukemia (AML) patients who had achieved Complete Remission (CR) after (re)induction/consolidation chemotherapy will receive the infusion of alloreactive NK cells.
- Trial name
- NKAML (NCT03955848)
- Testing
- Alloreactive NK cell infusion
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Leukemia, Erythroblastic, Acute, Myelodysplastic Syndromes
Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR
The purpose of this study is to determine whether 5-Azacytidine priming before the conditioning regimen for subjects receiving a hematopoietic stem cell transplant is an effective treatment for high risk myeloid malignancies in…
- Trial name
- NCT02497404
- Testing
- 5-Azacytidine, Fludarabine, Melphalan
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Weill Medical College of Cornell University
Chronic Myeloid Leukemia
Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
The goal of this clinical research study is to find out if treatment with a combination of dasatinib plus ropeginterferon can help to control CML-CP. The safety of this combination will also be studied.
- Trial name
- NCT07269470
- Testing
- Dasatinib, Ropeginterferon alfa-2b (P1101)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia, Myelodysplastic Syndromes
Early Discharge and Outpatient Care After Chemotherapy in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
RATIONALE: Gathering information about patients with myelodysplastic syndrome or acute myeloid leukemia who are discharged after finishing chemotherapy, or who stay in the hospital until blood counts return to normal, may help…
- Trial name
- NCT00844441
- Testing
- medical chart review, questionnaire administration, quality-of-life assessment
- Where
- 3 sites in United States, Switzerland
- Volunteers
- 96 people
- Sponsor
- Fred Hutchinson Cancer Center
Acute Myeloid Leukemia, Acute Undifferentiated Leukemia
Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse
This phase I/II trial studies the safety, side effects, and best dose of decitabine in combination with fludarabine, cytarabine, filgrastim, and idarubicin (FLAG-Ida) and total body irradiation (TBI) followed by a donor stem cell…
- Conditions
- Acute Myeloid Leukemia, Acute Undifferentiated Leukemia, Mixed Phenotype Acute Leukemia, Recurrent Acute Myeloid Leukemia
- Trial name
- NCT06928662
- Testing
- Decitabine, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.